Philips Launches IntraSight Plus, a Revolutionary Platform for Interventional Cardiology
Royal Philips announces the launch of IntraSight Plus, its integrated interventional imaging platform, now approved for sale in the United States and Europe. This solution combines diagnostic and therapeutic planning tools into a single system for percutaneous cardiac interventions.
IntraSight Plus merges Philips' IntraSight and SyncVision technologies. The platform incorporates Class IA intravascular ultrasound imaging, physiological assessment (iFR/FFR), co-registration, and real-time visualization of medical devices. It enables interventional cardiologists to diagnose, virtually plan treatment, guide device placement, and verify outcomes on a single screen. This approach addresses the challenges posed by the fragmentation of current systems, where intravascular ultrasound imaging and physiological measurements are typically separate.
Seamless Integration into Existing Philips Ecosystem
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
IntraSight Plus integrates seamlessly with the existing Philips ecosystem, including the Azurion interventional platform and PACS systems, enhancing interoperability within Philips-equipped catheterization labs. The first clinical case was performed on March 19, 2026, at the Cellitinnen-Krankenhaus St. Vinzenz hospital in Cologne, Germany, by Prof. Dr. Jan-Malte Sinning. The platform has received CE marking in Europe and FDA 510(k) clearance in the United States. Commercial availability is subject to market launch conditions and applicable regulatory requirements.
SectorSanté · Technologie · Dispositifs médicaux›Équipements Médicaux
Context
Period
Period: 1T2026
Key reported figures
Revenue: 3.9MD€
Free cash flow: 28M€
Guidance from the release
Nous avons délivré un bon départ en 2026.
Bonne performance au T1, croissance des ventes et des marges.
Risks mentioned
Impact des tarifs et inflation des coûts sur les marges.
Environnement macroéconomique incertain impactant les performances.
Opportunities identified
Croissance des ventes comparables de 4% dans tous les segments.
Augmentation du carnet de commandes grâce à des innovations.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
